Image

Belgium-based ThromboGenics has received a €3m grant (approximately $4.2m) from the Flemish agency for innovation by science and technology (IWT) for supporting new research into potential new biotherapeutics to treat diabetic macular edema (DME).

DME is a sight-threatening condition occuring in type 1 and type 2 diabetes patients, due to fluid leakage into the area of the retina.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

ThromboGenics will use the IWT funding for developing a much better understanding of the role of a novel pathway in diabetic macular edema as the basis for discovering new pre-clinical therapeutic candidates.

The company will develop new in-vitro assays and in-vivo models for identifying biotherapeutics that activate the pathway.

This will help the company in identifying pre-clinical candidates that meet a target product profile based around in-vitro potency, in-vivo efficacy and drug such as properties.

“We believe that by gaining a greater understanding of this novel pathway we may be able to discover and develop new biotherapeutics that could play a key role in the treatment of diabetic macular edema.”

ThromboGenics will generate these new candidates using the AMP-Rx protein design technology, which the company licensed from Eleven Biotherapeutics in May 2013.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

ThromboGenics CEO Dr Patrik De Haes said the award of this grant from IWT will enable the company to continue to progress its research activities in the field of diabetic eye disease.

“We believe that by gaining a greater understanding of this novel pathway we may be able to discover and develop new biotherapeutics that could play a key role in the treatment of diabetic macular edema.

“DME is a very prevalent condition where there is still scope to improve on the clinical outcomes delivered by current treatment options including laser coagulation, anti-VEGF antibodies and steroids,” Haes said.

ThromboGenics’ new biotherapeutics are aimed at reducing the vascular leakage and inflammation.

Image: Diabetic macular edema. Photo: courtesy of GeeJo.